Yufeng Liang

Dr. Yufeng Liang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
YLYufeng Liang
Yufeng Liang
JWJianxin Wan
Jianxin Wan
Yongping ChenYongping Chen
Yongping Chen
YPYangbin Pan
Yangbin Pan
Background: The diagnostic value of serum M-type phospholipase A2 receptor antibody (sPLA2R-ab) expression in patients with primary membranous nephropathy (PMN) has been established. However, the association between sPLA2R-ab and clinical remission remains uncertain. Methods: We systematically searched the literature for clinical trials regarding the correlation between sPLA2R-ab expression and clinical remission of PMN patients. Meta-analysis was performed to determine this association. Subgroup analysis, funnel plots, and sensitivity analysis were also performed to investigate heterogeneity or bias. Results: A total of 11 trials involving 824 patients were included. Patients with positive sPLA2R-ab had a poor clinical remission rate (RR = 0.76, 95%CI 0.68–0.86, P < 0.0001; I2 = 39%), a higher titer of sPLA2R-ab had a lower chance of clinical remission (RR = 0.72, 95%CI 0.59–0.87, P = 0.0006; I2 = 42%),and a higher risk of renal failure (RR = 4.85, 95% CI, 1.83–12.85, P = 0.002; I2 = 0%), without affecting relapse (RR = 0.97, 95% CI, 0.55–1.70; P = 0.92, I2 = 0%). Subgroup analysis by treatment strategies, assay methods, ethnicity, gender, renal function, the approach of ruling out SMN, and the ratio of patients with nephrotic-range proteinuria at baseline showed no significant association between these factors with the prognostic value of sPLA2R-ab for PMN patients. No significant publication bias was found. Conclusion: This meta-analysis adds to the evidence for current guidelines that sPLA2R-ab acts as not only a diagnostic marker but also a pivotal predictor for clinical remission. Therefore, sPLA2R-ab can be considered as a prognostic factor for stratifying PMN patients.

1 January 2024 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YLYufeng Liang
Yufeng Liang
JLJiaqun Lin
Jiaqun Lin
BHBinsan Huang
Binsan Huang
MWMengjie Weng
Mengjie Weng
TZTingting Zhen
Tingting Zhen
JWJianxin Wan
Jianxin Wan
Background: Tubulointerstitial injury plays a pivotal role in the progression of diabetic kidney disease (DKD), yet the link between neutrophil extracellular traps (NETs) and diabetic tubulointerstitial injury is still unclear.Methods: We analyzed microarray data (GSE30122) from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) associated with DKD’s tubulointerstitial injury. Functional and pathway enrichment analyses were conducted to elucidate the involved biological processes (BP) and pathways. Weighted gene coexpression network analysis (WGCNA) identified modules associated with DKD. LASSO regression and random forest selected NET‐related characteristic genes (NRGs) related to DKD tubulointerstitial injury.Results: Eight hundred ninety‐eight DEGs were identified from the GSE30122 dataset. A significant module associated with diabetic tubulointerstitial injury overlapped with 15 NRGs. The hub genes, CASP1 and LYZ, were identified as potential biomarkers. Functional enrichment linked these genes with immune cell trafficking, metabolic alterations, and inflammatory responses. NRGs negatively correlated with glomerular filtration rate (GFR) in the Neph v5 database. Immunohistochemistry (IHC) validated increased NRGs in DKD tubulointerstitial injury.Conclusion: Our findings suggest that the CASP1 and LYZ genes may serve as potential diagnostic biomarkers for diabetic tubulointerstitial injury. Furthermore, NRGs involved in diabetic tubulointerstitial injury could emerge as prospective targets for the diagnosis and treatment of DKD.

30 August 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
LQLi Qiu
Li Qiu
BHBinsan Huang
Binsan Huang
QLQiaozhen Liao
Qiaozhen Liao
CLChenglun Li
Chenglun Li
AWAzhen Wang
Azhen Wang
YLYufeng Liang
Yufeng Liang
Pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) represents a significant complication with incompletely understood pathogenesis. Notably, podocytic infolding glomerulopathy (PIG), a rare pathological phenomenon in SLE-related renal lesions, has not been previously linked to PAH development. The cardiovascular safety profile of belimumab, a biologic agent for SLE treatment, requires continued surveillance, particularly regarding potential pulmonary vascular complications. We report a 30-year-old male with SLE who unexpectedly developed severe PAH following complete remission of class V lupus nephritis. The patient’s renal pathology exhibited PIG features, initially overlooked at diagnosis. Despite rapid improvement in renal function with conventional immunosuppression, PAH persisted, suggesting the critical role of vascular remodeling in PAH perpetuation. Glucocorticoid therapy resulted in avascular necrosis of the femoral head. Notably, PAH emerged during belimumab treatment and showed remarkable improvement following belimumab discontinuation, raising important concerns about potential therapy-related cardiovascular complications. Pulmonary arterial pressure significantly decreased with marked symptomatic improvement. This case underscores the necessity for clinical vigilance in SLE management.For patients with SLE-PIG, close monitoring for potential PAH development is essential, even after apparent SLE remission. Most critically, this case highlights potential cardiovascular safety signals associated with belimumab therapy, emphasizing the need for systematic monitoring of pulmonary vascular complications in patients receiving novel biologic treatments—an observation warranting urgent verification in future clinical investigations. Not applicable.